Bioharvest Sciences Inc. (Nasdaq: BHST), an SEC filer in Pharmaceutical Preparations, closed at $1.84, -0.5%, on 2026-08-28, with a market cap of $42M as of 2026-08-27, a return on equity of -83.2% and a net margin of -32.3%. Institutional ownership, earnings history and filed financials are on the tabs below.
| Market Cap | $41.7M | |
| Enterprise Value | — | |
| Revenue | — | — |
| Gross Profit | $20.5M | +46.9% |
| EBITDA | — | — |
| Net Income | -$11.1M | — |
| Diluted EPS | — | — |
| Free Cash Flow | — | — |
Bars are the value as filed for every stored fiscal year (oldest → newest, the latest bar solid); a year the store has no value for is left EMPTY. Free cash flow is operating cash flow less capital expenditures for the same year — the only figure here computed from two lines, and a year missing either one is a gap. The 3y/5y/10y CAGRs are the analytics core’s own (positive-base only); no rate is recomputed on this strip, and no rate is shown for a series the core doesn’t publish one for. Diluted EPS is drawn on ONE share basis: as-filed per-share figures from before a split are stated on the old basis, so where the implied share count breaks (net income ÷ EPS, ±1.45× band — the same acceptance band the API’s own classifier uses) the earlier bars are left undrawn and any CAGR horizon reaching past the break is suppressed rather than shown as a rate across two different bases.
The bridge draws from revenue and net income — it appears once a period carries both.
Sector is SIC-based, not GICS. A blank cell means the figure wasn't filed.
